In line Q1 and on track deleveraging; worth a go
15/05/24 -"The Q1 results largely met the consensus, as the firm’s key blood-plasma-derived proteins witnessed strong demand, profitability continued to expand yoy and the deleveraging initiatives remained on ..."
Pages
54
Language
English
Published on
15/05/24
You may also be interested by these reports :
22/10/26
The Q3 sales were ahead of the street’s expectations, driven by healthy growth across both segments. The beat, though, received support from a ...
22/10/26
Ipsen reported a robust Q3, resulting in an upgraded 2026 guidance. While we may revise our estimates upwards, we do not anticipate a significant ...
22/10/26
A guidance upgrade on top of the modest outlook uplift in July 2026 reflects UCB’s habit of making modest promises and then over-delivering. ...
20/10/26
The Q3 sales growth surpassed the full-year guidance range, backed by healthy growth in companion and farm animal segments across geographies. The ...